protocol CNTO1275PSA3001, A phase 3 multicenter, randomized, double-blind, placebo-controlled trial of ustikinumab, a fully human anti il-12/23p40 monoclonal antibody, admistered subcutaneously, in subjects with active psoriasis arthritis, Psummit I